Announcement & Notice - Disclosure - Investor Relations

Corporate Governance Stock Information Disclosure Financials Presentations and Events Analyst Coverage Notices-Replacement of Lost Share Certificates Subscribe to Updates

Home > Investor Relations > Disclosure

Disclosure

Listing Documents Financial Report/ESG information Announcement & Notice IR Journal

2022-02-09

Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2022
2022-01-24

VOLUNTARY ANNOUNCEMENT - DOSING OF FIRST PATIENT IN PHIB/IIA TRIAL OF NEXT-GENERATION ANTI-CTLA-4 ANTIBODY IN CHINA
2022-01-13

VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST INTERIM ANALYSIS OF PHASE III CLINICAL TRIAL OF TANFANERCEPT (HBM9036)
2022-01-06

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021
2022-01-03

VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST DOSING OF FIRST PATIENT WITH TWO HBM4003 PHASE I TRIALS
2021-12-30

VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE BY THE TRUSTEE PURSUANT TO THE SHARE AWARD SCHEME
2021-12-05

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2021
2021-11-05

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2021
2021-10-19

VOLUNTARY ANNOUNCEMENT – COMPLETION OF FIRST DOSING OF FIRST PATIENT WITH BATOCLIMAB (HBM9161) PHASE II TRIAL FOR TREATMENT OF THYROID EYE DISEASE
2021-10-07

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2021
2021-09-27

VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST DOSING OF FIRST PATIENT WITH BATOCLIMAB (HBM9161) PHASE III TRIAL FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS
2021-09-17

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
2021-09-17

CHANGE OF EXECUTIVE DIRECTOR
2021-09-13

VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS FROM PHASE I STUDY AND ABSTRACTS OF PHASE I DATA OF NEXT-GENERATION ANTI-CTLA-4 ANTIBODY HBM4003
2021-09-10

VOLUNTARY ANNOUNCEMENT - CHINESE REGULATORY APPROVAL OF TWO IND APPLICATIONS FOR NEXT-GENERATION ANTI-CTLA-4 ANTIBODY HBM4003
2021-09-06

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2021
2021-08-31

VOLUNTARY ANNOUNCEMENT - HARBOUR BIOMED RECEIVES CHINESE REGULATORY APPROVAL OF IND APPLICATION TO BEGIN PHASE II CLINICAL TRIAL OF HBM9161 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)
2021-08-30

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2021
2021-08-05

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2021
2021-07-26

VOLUNTARY ANNOUNCEMENT - ABSTRACTS OF PHASE I DATA OF NEXT-GENERATION ANTI-CTLA-4 ANTIBODY HBM4003 TO BE PRESENTED AT ESMO CONGRESS 2021

1 ···17 18 ···21